Multiple Sclerosis Center, "A. Cardarelli" Hospital, Naples, Italy.
Neurological Clinic and Stroke Unit, "A. Cardarelli" Hospital, Naples, Italy.
Neurol Sci. 2021 Apr;42(4):1531-1534. doi: 10.1007/s10072-020-04892-7. Epub 2020 Nov 14.
Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are new emerging diseases with heterogeneous course, treatment, response, and prognosis.
We herein present 2 cases with antibodies to MOG, one with a cerebellar/brainstem monophasic syndrome which partially improved after treatment, and the other with an optic neuritis onset then relapsed with cortical encephalitis and presented a subsequent complete recovery. We further discuss elements possibly associated with disease heterogeneity and influencing treatment choices.
MOGAD is an extremely variable disease which can relapse and accumulate disability over time. An early diagnosis and correct timely treatment is fundamental to improve clinical outcome.
抗髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种新出现的具有不同病程、治疗、反应和预后的疾病。
本文介绍了 2 例抗 MOG 抗体患者，1 例表现为小脑/脑干单相综合征，治疗后部分改善，另 1 例表现为视神经炎，随后复发为皮质脑炎，随后完全恢复。我们进一步讨论了可能与疾病异质性和影响治疗选择相关的因素。
MOGAD 是一种极其多变的疾病，随着时间的推移可能会复发并累积残疾。早期诊断和正确及时的治疗是改善临床结局的关键。
